FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average but	ırden
hours per response	0 !

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(e Responses)														
1. Name and Address of Reporting Person *- VANCE DOLLY				2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD. (Street) SOUTH SAN FRANCISCO, CA 94080				Date of Earliest Transaction (Month/Day/Year) 01/23/2019 4. If Amendment, Date Original Filed(Month/Day/Year)						X Officer (give title below) Other (specify below) EVP Corp. Affairs, G.C., Sect. 6. Individual or Joint/Group Filing(Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
									X						
(City)		(State)	(Zip)	Table I - Non-Derivative Securities Acqu				s Acquired	nired, Disposed of, or Beneficially Owned						
1.Title of Se (Instr. 3)	Date			ZA. Deemed Execution Date, if Code (A) or Disposed o (Instr. 8) (Month/Day/Year) Code V Amount (D)		f (D) Ow Tra	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		G F I C (Ownership orm: Oirect (D) r Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
			Table II					in this fo a currentired, Dispos	who respond orm are not re tly valid OMB ed of, or Benef vertible securit	quired to control r	respond ur number.				1474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if	4. Transac Code	tion		r of (A) ed of	in this fo a currentired, Dispos	orm are not re tly valid OMB ed of, or Benef vertible securit reisable and Date	quired to control r icially Ow	respond un number. ned d Amount ying	nless the f	orm displays 9. Number of	10. Owners Form of Derivati Security Direct (or Indire	11. Naturini of Indirect Beneficie Ownersh (Instr. 4)
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if any	4. Transac Code	tion	5. Number Derivative Securities Acquired (or Dispose (D) (Instr. 3, 4	r of (A) ed of	in this fo a current ired, Dispos options, con 6. Date Exer Expiration I	erm are not rettly valid OMB ed of, or Benef vertible securit recisable and Date t/Year) Expiration	quired to control r icially Ow ties) 7. Title an of Underly Securities	respond un number. ned d Amount ying	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	10. Owners Form of Derivati Security Direct (or Indire	11. Natur of Indire Beneficia Ownersh (Instr. 4)

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
VANCE DOLLY RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080			EVP Corp. Affairs, G.C., Sect.		

Signatures

/s/Dolly Vance	01/25/2019
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares of common stock subject to the option vest in equal monthly installments over four (4) years from the vesting commencement date of January 1, 2019.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.